Mod GRF 1-29 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Mod GRF 1-29 evidence and protocol review

Growth Signal Research peptide Lyophilized verified

Also known as: Modified GRF 1-29, CJC-1295 No DAC

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

2 mg, 5 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA. NOTE: duplicate of cjc1295-5mg - recommend merging catalog entries.

Solubility

Lyophilized; reconstitute in sterile bacteriostatic water

Catalog Description

Mod GRF 1-29 (Modified GRF 1-29) is an alternate name used by some vendors and research communities for the same growth-hormone-releasing hormone (GHRH) analog listed in this catalog as CJC-1295 No DAC (a 29-amino-acid GHRH fragment with four stabilizing substitutions and no albumin-binding moiety, giving it a short circulating half-life of roughly 30 minutes). Because the two names refer to the identical peptide sequence, this record intentionally mirrors the CJC-1295 No DAC record's sourcing, effects, protocols, and side-effect data rather than duplicating independent research; consult the CJC-1295 No DAC record (slug cjc1295-5mg) as the canonical entry.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Not established for exact Mod GRF(1-29); the 5.8-8.1 day CJC-1295 value belongs to the albumin-binding DAC molecule and must not be reused

Onset

Rapid, transient GH pulse per dose

Administration Routes (Research)

No validated human route for the exact catalog identity

Reported Research Effects

GHRH receptor agonism (pulsatile GH release model) - identical compound to CJC-1295 No DAC

Reported Research Side Effects

No adequate human safety profile for exact non-DAC Mod GRF(1-29)
GH-axis stimulation may affect glucose handling, edema, arthralgia, headache, and IGF-I
CJC-1295-DAC safety and long half-life cannot be assigned to the non-DAC peptide

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

No exact human administration study for the non-DAC modified GRF(1-29) identity was located in the audited literature set [Research only; Not established; Not established]Source: identity-specific evidence review
CJC-1295 with drug-affinity-complex component was tested at 30 or 60 mcg/kg SC in healthy adults and produced prolonged GH and IGF-I elevation [SC; Comparator molecule only, not transferable to Mod GRF(1-29); Single or repeated weekly/biweekly doses]Source: PMID 16352683

Research Notes

The key correction is identity control: Mod GRF(1-29), often sold as CJC-1295 no-DAC, is not the albumin-binding CJC-1295-DAC molecule used in the cited long-acting human trials. Those trial doses are retained only as an explicitly non-transferable comparator.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

CJC-1295 DAC healthy-adult pharmacokinetic and pharmacodynamic trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/16352683/

CJC-1295 DAC pulsatile GH study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/17018654/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.